senicapoc has been researched along with Anemia, Hemolytic, Congenital in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Badens, C; Guizouarn, H; Rapetti-Mauss, R; Soriani, O; Vinti, H | 1 |
| Alper, SL; Brugnara, C; Fikry, CC; Gallagher, DR; Kuypers, FA; Rivera, A; Shmukler, BE; Snyder, LM; Vandorpe, DH | 1 |
2 other study(ies) available for senicapoc and Anemia, Hemolytic, Congenital
| Article | Year |
|---|---|
Senicapoc: a potent candidate for the treatment of a subset of hereditary xerocytosis caused by mutations in the Gardos channel.
Topics: Acetamides; Anemia, Hemolytic, Congenital; Erythrocytes; HEK293 Cells; Humans; Hydrops Fetalis; Intermediate-Conductance Calcium-Activated Potassium Channels; Mutation; Potassium; Transfection; Trityl Compounds | 2016 |
Erythrocytes from hereditary xerocytosis patients heterozygous for KCNN4 V282M exhibit increased spontaneous Gardos channel-like activity inhibited by senicapoc.
Topics: Acetamides; Anemia, Hemolytic, Congenital; Cell Count; Drug Evaluation, Preclinical; Erythrocyte Deformability; Erythrocytes; Gain of Function Mutation; Heterozygote; Humans; Hydrops Fetalis; In Vitro Techniques; Intermediate-Conductance Calcium-Activated Potassium Channels; Ion Transport; Mutation, Missense; Osmotic Fragility; Patch-Clamp Techniques; Potassium; Potassium Channel Blockers; Trityl Compounds | 2017 |